Effects of Acetylcysteine Effervescent Tablets combined with Salbutamol Sulfate on Pulmonary Function and Serum Soluble Myeloid Cell-triggering Receptor-1 in Patients with Stable COPD
CAI Rangji, et al
Qinghai People's Hospital, Qinghai Xining 810007, China
Abstract：Objective: To investigate the relationship between acetylcysteine effervescent tablets and salbutamol sulfate aerosol in the stable period lung function and serum soluble myeloid cell trigger receptor-1 (sTREM-1) in patients with chronic obstructive pulmonary disease (COPD). Methods: 82 patients with COPD in our hospital (November 2016-August 2018) were enrolled according to the treatment plan (n=41) and the control group (n=41). On the basis of conventional treatment, the control group was treated with salbutamol sulfate aerosol, and the study group was treated with acetylcysteine effervescent tablets on the basis of the control group for 10 days. The two groups of clinical symptoms (pulmonary signs, wheezing, dyspnea, cough) were relieved, clinical efficacy, lung function indicators before and after treatment [forced vital capacity (FVC), 1st s forced breathing volume (FEV1), FEV1 /FVC] levels, serum sTREM-1 and inflammatory factors [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-8] levels, adverse reactions (headache, gastrointestinal tract The incidence of discomfort, itching, vomiting and nausea were counted. Results: ①Clinical symptoms: The lung signs, wheezing, dyspnea, and cough disappeared in the study group were shorter than the control group (P<0.05). ②Clinical efficacy: the total effective rate of the study group was 95.12% (39/41). 78.05% (32/41) in the control group (P<0.05); ③Pulmonary function: The levels of FVC, FEV1, and FEV1/FVC increased after treatment at the end of the two groups, and the study group was higher than the control group (P<0.05); ④serum sTREM-1 and inflammatory factors: serum sTREM-1 and TNF-α, IL-6, IL-8 levels were lower than before treatment, and the study group was lower than the control group ( P<0.05); ⑤Adverse reactions: The incidence of adverse reactions in the study group was 14.63% (6/41) and there was no significant difference between the control group and 9.76% (4/41) (P>0.05). Conclusion: The combination of salbutamol sulfate aerosol and acetylcysteine effervescent tablets in the treatment of patients with stable COPD can effectively shorten the time of clinical symptom relief, reduce serum inflammatory factors and sTREM-1 levels, and reduce the degree of inflammatory response in vivo, inhibit the disease, promote the early recovery of lung function, and does not increase the risk of adverse reactions, and is safe.
才让吉, 包八月, 才让卓玛, 宋康, 陈寒杰. 乙酰半胱氨酸泡腾片联合硫酸沙丁胺醇气雾剂对COPD患者稳定期肺功能及血清可溶性髓样细胞触发受体-1的影响[J]. 河北医学, 2019, 25(5): 716-721.
CAI Rangji, et al. Effects of Acetylcysteine Effervescent Tablets combined with Salbutamol Sulfate on Pulmonary Function and Serum Soluble Myeloid Cell-triggering Receptor-1 in Patients with Stable COPD. HeBei Med, 2019, 25(5): 716-721.
2019, Vol. 25 
冀公网安备13080202000677号